Related Experiment Video
Updated: Aug 13, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Towards targeted therapy for infant acute lymphoblastic leukaemia
Ronald W Stam1, Monique L den Boer, Rob Pieters
1Department of Paediatric Oncology/Haematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
British Journal of Haematology
|February 1, 2006
Summary
Infant acute lymphoblastic leukemia (ALL) treatments fail over 50% of young patients. Understanding infant ALL biology is key to developing better therapies and improving survival rates for these children.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Biology
Background:
- Childhood acute lymphoblastic leukemia (ALL) has improved survival rates, reaching approximately 80% long-term survival.
- However, current treatments are ineffective in over 50% of infant ALL cases, highlighting a critical unmet need.
- Infant ALL presents unique biological characteristics that differentiate it from older pediatric and adult ALL.
Purpose of the Study:
- To review the current understanding of infant acute lymphoblastic leukemia (ALL) biology.
- To explore how this biological knowledge can inform the development of novel therapeutic strategies.
- To improve the prognosis and treatment outcomes for infants diagnosed with ALL.
Main Methods:
- Literature review of existing studies on infant ALL biology.
- Analysis of current treatment strategies and their limitations in infant ALL.
- Synthesis of biological insights to propose innovative therapeutic approaches.
Main Results:
- Infant ALL exhibits distinct genetic and molecular features compared to other age groups.
- Specific biological pathways are dysregulated in infant ALL, offering potential therapeutic targets.
- Current treatment regimens often fail due to the unique biology and immature immune system of infants.
Conclusions:
- A deeper understanding of infant ALL biology is crucial for developing more effective treatments.
- Targeting specific molecular pathways identified in infant ALL may lead to improved therapeutic efficacy.
- Innovative treatment strategies based on biological insights are urgently needed to enhance survival rates for infants with ALL.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...